SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $51,354.36 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer directly owned 670,651 shares in the company, valued at $3,500,798.22. The trade was a 1.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, June 22nd, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.38, for a total transaction of $2,270.36.
• On Monday, April 20th, Ross Muken sold 760 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,952.00.
• On Tuesday, April 14th, Ross Muken sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total transaction of $13,888.00.
• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $21,143.92.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.69, for a total transaction of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,484.24.

SOPHiA GENETICS Trading Up 5.6%

Shares of SOPHiA GENETICS stock opened at $5.82 on Friday. The business has a fifty day simple moving average of $5.16 and a two-hundred day simple moving average of $4.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company has a market capitalization of $488.24 million, a price-to-earnings ratio of -11.19 and a beta of 0.96. SOPHiA GENETICS SA has a 1 year low of $2.92 and a 1 year high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently modified their holdings of the business. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter valued at $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.